+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cancer Pain Market by Drug Type and Disease Indication: Global Opportunity Analysis and Industry Forecast, 2018 - 2025

  • ID: 4730343
  • Report
  • December 2018
  • Region: Global
  • 177 pages
  • Allied Analytics LLP
1 of 4
Cancer Pain Market Overview:

The global cancer pain market generated $5,285 million in 2017, and is projected to reach $7,545 million by 2025, growing at a CAGR of 4.5% from 2018 to 2025.

Cancer pain can be due to the disease condition itself or may be due to the associated treatments such as surgeries, chemotherapy, and other therapies. There is surge in the demand for cancer pain drugs owing to the growth in incidence of different forms of cancer, higher number of R&D studies to develop cancer pain therapeutics, and increase in adoption of cancer pain drugs. In addition, growth in the geriatric population and wide availability of cancer pain drugs further drive the market growth. However, adverse effects associated with cancer pain are projected to impede the market growth.

The global cancer pain market is segmented based on drug type, disease indication, and region. Based on drug type, the market is classified into opioids, non-opioids, and nerve blockers. According to the disease indication, the market is categorized into lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer, and others. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil and rest of LAMEA).

Key Benefits for Cancer Pain Market:

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

Cancer Pain Key Market Segments:

By Drug Type

Opioids
Non-Opioids
Nerve Blockers

By Application

Lung Cancer
Bladder Cancer
Melanoma
Hodgkin Lymphoma
Others

By Region

North America
U.S.
Canada
Mexico

Europe
Germany
France
UK
Rest of Europe

Asia-Pacific
Japan
China
Australia
India
Rest of Asia-Pacific

LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

List Of Key Players Profiled in the Report

Aoxing Pharmaceutical Company, Inc.
BioDelivery Sciences International, Inc.
Daiichi Sankyo Co., Ltd.
Grunenthal Pharma GmbH & Co. KG
Hisamitsu Pharmaceutical Co, Inc.
Insys Therapeutics, Inc.
Mundipharma International Limited
Orexo AB
Pfizer Inc.
Teva Pharmaceutical Industries Limited

List Of Other Players in the Value Chain(These players are not profiled in the report. The same will be included on request.)

Eli Lilly and Company
Galena Biopharma
Kyowa Kirin International plc
Meda Pharmaceuticals
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top player positioning
3.3. Market dynamics
3.3.1. Drivers
3.3.1.1. Rise in incidence of cancer across the globe
3.3.1.2. Surge in global geriatric population
3.3.1.3. Increase in healthcare expenditure worldwide
3.3.2. Restraints
3.3.2.1. Adverse effects associated with the use of drugs employed in cancer pain management
3.3.3. Opportunities
3.3.3.1. Increase in number of pipeline drugs
3.3.3.2. Growth opportunities in emerging markets
3.3.4. Impact analyses

CHAPTER 4: CANCER PAIN MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Opioids
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by type
4.2.2.1. Morphine
4.2.2.1.1. Market size and forecast
4.2.2.2. Fentanyl
4.2.2.2.1. Market size and forecast
4.2.2.3. Others
4.2.2.3.1. Market size and forecast
4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country
4.3. Non-opioids
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by type
4.3.2.1. Acetaminophen
4.3.2.1.1. Market size and forecast
4.3.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
4.3.2.2.1. Market size and forecast
4.3.3. Market size and forecast, by region
4.3.4. Market analysis, by country
4.4. Nerve blockers
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

CHAPTER 5: CANCER PAIN MARKET, BY DISEASE INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Lung cancer
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Colorectal cancer
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Breast cancer
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.5. Prostate cancer
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
5.6. Blood cancer
5.6.1. Market size and forecast
5.6.2. Market analysis, by country
5.7. Others
5.7.1. Market size and forecast
5.7.2. Market analysis, by country

CHAPTER 6: CANCER PAIN MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by type
6.2.2.1.2. U.S. market size and forecast, by disease indication
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by type
6.2.2.2.2. Canada market size and forecast, by disease indication
6.2.2.3. Mexico
6.2.2.3.1. Mexico market size and forecast, by type
6.2.2.3.2. Mexico market size and forecast, by disease indication
6.2.3. Market size and forecast, by type
6.2.4. Market size and forecast, by disease indication
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by type
6.3.2.1.2. Germany market size and forecast, by disease indication
6.3.2.2. France
6.3.2.2.1. France market size and forecast, by type
6.3.2.2.2. France market size and forecast, by disease indication
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by type
6.3.2.3.2. UK market size and forecast, by disease indication
6.3.2.4. Italy
6.3.2.4.1. Italy market size and forecast, by type
6.3.2.4.2. Italy market size and forecast, by disease indication
6.3.2.5. Spain
6.3.2.5.1. Spain market size and forecast, by type
6.3.2.5.2. Spain market size and forecast, by disease indication
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe market size and forecast, by type
6.3.2.6.2. Rest of Europe market size and forecast, by disease indication
6.3.3. Market size and forecast, by type
6.3.4. Market size and forecast, by disease indication
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan market size and forecast, by type
6.4.2.1.2. Japan market size and forecast, by disease indication
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by type
6.4.2.2.2. China market size and forecast, by disease indication
6.4.2.3. Australia
6.4.2.3.1. Australia market size and forecast, by type
6.4.2.3.2. Australia market size and forecast, by disease indication
6.4.2.4. India
6.4.2.4.1. India market size and forecast, by type
6.4.2.4.2. India market size and forecast, by disease indication
6.4.2.5. Rest of Asia-Pacific
6.4.2.5.1. Rest of Asia- Pacific market size and forecast, by type
6.4.2.5.2. Rest of Asia- Pacific market size and forecast, by disease indication
6.4.3. Market size and forecast, by type
6.4.4. Market size and forecast, by disease indication
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil market size and forecast, by type
6.5.2.1.2. Brazil market size and forecast, by disease indication
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia market size and forecast, by type
6.5.2.2.2. Saudi Arabia market size and forecast, by disease indication
6.5.2.3. South Africa
6.5.2.3.1. South Africa market size and forecast, by type
6.5.2.3.2. South Africa market size and forecast, by disease indication
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA market size and forecast, by type
6.5.2.4.2. Rest of LAMEA market size and forecast, by disease indication
6.5.3. Market size and forecast, by type
6.5.4. Market volume and forecast, by disease indication

CHAPTER 7: COMPANY PROFILES
7.1. AOXING PHARMACEUTICAL COMPANY, INC.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance
7.2. BIODELIVERY SCIENCES INTERNATIONAL, INC.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product Portfolio
7.2.5. Business performance
7.3. DAIICHI SANKYO CO., LTD.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Product Portfolio
7.3.4. Business performance
7.3.5. Key strategic moves and developments
7.4. GRNENTHAL PHARMA GmbH & CO. KG
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Product Portfolio
7.5. HISAMITSU PHARMACEUTICAL CO., INC.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. INSYS THERAPEUTICS, INC.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.7. MUNDIPHARMA INTERNATIONAL LIMITED
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Product Portfolio
7.8. OREXO AB
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance
7.9. PFIZER INC.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance
7.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance

List Of Tables

Table 01. Global Cancer Pain Market, By Drug Type, 2017-2025 ($Million)
Table 02. Opioids Market, By Type, 2017-2025 ($Million)
Table 03. Opioids Market, By Region, 2017-2025 ($Million)
Table 04. Non-Opioids Market, By Type, 2017-2025 ($Million)
Table 05. Non-Opioids Market, By Region, 2017-2025 ($Million)
Table 06. Nerve Blockers Market, By Region, 2017-2025 ($Million)
Table 07. Global Cancer Pain Market, By Application, 2017-2025 ($Million)
Table 08. Lung Cancer Pain Market, By Region, 2017-2025 ($Million)
Table 09. Colorectal Cancer Pain Market, By Region, 2017-2025 ($Million)
Table 10. Breast Cancer Pain Market, By Region, 2017-2025 ($Million)
Table 11. Prostate Cancer Pain Market, By Region, 2017-2025 ($Million)
Table 12. Blood Cancer Pain Market, By Region, 2017-2025 ($Million)
Table 13. Cancer Pain Market For Other Disease Indication, By Region, 2017-2025 ($Million)
Table 14. Cancer Pain Market Revenue, By Region, 2017-2025 ($Million)
Table 15. North America Cancer Pain Market Revenue, By Country, 2017-2025 ($Million)
Table 16. U.S. Cancer Pain Market, By Type, 20162023 ($Million)
Table 17. U.S. Cancer Pain Market, By Disease Indication, 20162023 ($Million)
Table 18. Canada Cancer Pain Market, By Type, 20162023 ($Million)
Table 19. Canada Cancer Pain Market, By Disease Indication, 20162023 ($Million)
Table 20. Mexico Cancer Pain Market, By Type, 20162023 ($Million)
Table 21. Mexico Cancer Pain Market, By Disease Indication, 20162023 ($Million)
Table 22. North America Cancer Pain Market Revenue, By Type, 2017-2025 ($Million)
Table 23. North America Cancer Pain Market Revenue, By Disease Indication, 2017-2025 ($Million)
Table 24. Europe Cancer Pain Market Revenue, By Country, 2017-2025 ($Million)
Table 25. Germany Cancer Pain Market, By Type, 20162023 ($Million)
Table 26. Germany Cancer Pain Market, By Disease Indication, 20162023 ($Million)
Table 27. France Cancer Pain Market, By Type, 20162023 ($Million)
Table 28. France Cancer Pain Market, By Disease Indication, 20162023 ($Million)
Table 29. Uk Cancer Pain Market, By Type, 20162023 ($Million)
Table 30. Uk Cancer Pain Market, By Disease Indication, 20162023 ($Million)
Table 31. Italy Cancer Pain Market, By Type, 20162023 ($Million)
Table 32. Italy Cancer Pain Market, By Disease Indication, 20162023 ($Million)
Table 33. Spain Cancer Pain Market, By Type, 20162023 ($Million)
Table 34. Spain Cancer Pain Market, By Disease Indication, 20162023 ($Million)
Table 35. Rest Of Europe Cancer Pain Market, By Type, 20162023 ($Million)
Table 36. Rest Of Europe Cancer Pain Market, By Disease Indication, 20162023 ($Million)
Table 37. Europe Cancer Pain Market Revenue, By Type, 2017-2025 ($Million)
Table 38. Europe Cancer Pain Market Revenue, By Disease Indication, 2017-2025 ($Million)
Table 39. Asia-Pacific Cancer Pain Market Revenue, By Country, 2017-2025 ($Million)
Table 40. Japan Cancer Pain Market, By Type, 20162023 ($Million)
Table 41. Japan Cancer Pain Market, By Disease Indication, 20162023 ($Million)
Table 42. China Cancer Pain Market, By Type, 20162023 ($Million)
Table 43. China Cancer Pain Market, By Disease Indication, 20162023 ($Million)
Table 44. Australia Cancer Pain Market, By Type, 20162023 ($Million)
Table 45. Australia Cancer Pain Market, By Disease Indication, 20162023 ($Million)
Table 46. India Cancer Pain Market, By Type, 20162023 ($Million)
Table 47. India Cancer Pain Market, By Disease Indication, 20162023 ($Million)
Table 48. Rest Of Asia- Pacific Cancer Pain Market, By Type, 20162023 ($Million)
Table 49. Rest Of Asia- Pacific Cancer Pain Market, By Disease Indication, 20162023 ($Million)
Table 50. Asia-Pacific Cancer Pain Market Revenue, By Type, 2017-2025 ($Million)
Table 51. Asia-Pacific Cancer Pain Market Revenue, By Disease Indication, 2017-2025 ($Million)
Table 52. Lamea Cancer Pain Market Revenue, By Country, 2017-2025 ($Million)
Table 53. Brazil Cancer Pain Market, By Type, 20162023 ($Million)
Table 54. Brazil Cancer Pain Market, By Disease Indication, 20162023 ($Million)
Table 55. Saudi Arabia Cancer Pain Market, By Type, 20162023 ($Million)
Table 56. Saudi Arabia Cancer Pain Market, By Disease Indication, 20162023 ($Million)
Table 57. South Africa Cancer Pain Market, By Type, 20162023 ($Million)
Table 58. South Africa Cancer Pain Market, By Disease Indication, 20162023 ($Million)
Table 59. Rest Of Lamea Cancer Pain Market, By Type, 20162023 ($Million)
Table 60. Rest Of Lamea Cancer Pain Market, By Disease Indication, 20162023 ($Million)
Table 61. Lamea Cancer Pain Market Revenue, By Type, 2017-2025 ($Million)
Table 62. Lamea Cancer Pain Market Volume, By Disease Indication, 2017-2025 (Units)
Table 63. Aoxing Pharm: Company Snapshot
Table 64. Aoxing Pharm: Operating Segments
Table 65. Aoxing Pharm: Product Portfolio
Table 66. Bdsi: Company Snapshot
Table 67. Bdsi: Operating Segments
Table 68. Bdsi: Product Portfolio
Table 69. Daiichi Sankyo: Company Snapshot
Table 70. Daiichi Sankyo: Product Portfolio
Table 71. Grnenthal: Company Snapshot
Table 72. Grnenthal: Product Portfolio
Table 73. Hisamitsu Pharmaceutical: Company Snapshot
Table 74. Hisamitsu Pharmaceutical: Operating Segments
Table 75. Hisamitsu Pharmaceutical: Product Portfolio
Table 76. Insys: Company Snapshot
Table 77. Insys: Operating Segments
Table 78. Insys: Product Portfolio
Table 79. Mundipharma: Company Snapshot
Table 80. Mundipharma: Product Portfolio
Table 81. Orexo: Company Snapshot
Table 82. Orexo: Operating Segments
Table 83. Orexo: Product Portfolio
Table 84. Pfizer: Company Snapshot
Table 85. Pfizer: Operating Segments
Table 86. Pfizer: Product Portfolio
Table 87. Teva: Company Snapshot
Table 88. Teva: Operating Segments
Table 89. Teva: Product Portfolio

List Of Figures

Figure 01. Global Cancer Pain Market Segmentation
Figure 02. Top Investment Pockets
Figure 03. Top Player Positioning, 2017
Figure 04. World Population Aged 65 And Over (%)
Figure 05. Impact Analyses
Figure 06. Morphine Market For Cancer Pain, 2017-2025 ($Million)
Figure 07. Fentanyl Market For Cancer Pain, 2017-2025 ($Million)
Figure 08. Others Market For Cancer Pain, 2017-2025 ($Million)
Figure 09. Comparative Analysis Of Opioids Market, By Country, 2017 & 2025 (%)
Figure 10. Acetaminophen Market For Cancer Pain, 2017-2025 ($Million)
Figure 11. Non-Steroidal Anti-Inflammatory Drugs (Nsaids) Market For Cancer Pain, 2017-2025 ($Million)
Figure 12. Comparative Analysis Of Non-Opioids, Market, By Country, 2017 & 2025 (%)
Figure 13. Comparative Analysis Of Nerve Blockers Market, By Country, 2017 & 2025 (%)
Figure 14. Comparative Analysis Of Lung Cancer Pain Market, By Country, 2017 & 2025 (%)
Figure 15. Comparative Analysis Of Colorectal Cancer Pain Market, By Country, 2017 & 2025 (%)
Figure 16. Comparative Analysis Of Breast Cancer Pain Market, By Country, 2017 & 2025 (%)
Figure 17. Comparative Analysis Of Prostate Cancer Pain Market, By Country, 2017 & 2025 (%)
Figure 18. Comparative Analysis Of Blood Cancer Pain Market, By Country, 2017 & 2025 (%)
Figure 19. Comparative Analysis Of Cancer Pain Market For Other Indication Market, By Country, 2017 & 2025 (%)
Figure 20. Aoxing Pharm: Revenue, 20152017 ($Million)
Figure 21. Bdsi: Net Sales, 20152017 ($Million)
Figure 22. Daiichi Sankyo: Net Sales, 20152017 ($Million)
Figure 23. Hisamitsu Pharmaceutical Revenue, 20152017 ($Million)
Figure 24. Hisamitsu Pharmaceutical: Revenue Share By Business Segment, 2017 (%)
Figure 25. Hisamitsu Pharmaceutical: Revenue Share By Region, 2017 (%)
Figure 26. Insys: Net Sales, 20152017 ($Million)
Figure 27. Orexo: Revenue, 20152017 ($Million)
Figure 28. Orexo: Revenue Share By Region, 2017 (%)
Figure 29. Pfizer: Revenue, 20152017 ($Million)
Figure 30. Pfizer: Revenue Share By Segment, 2017 (%)
Figure 31. Pfizer: Revenue Share By Region, 2017 (%)
Figure 32. Teva: Revenue, 20152017 ($Million)
Figure 33. Teva: Revenue By Segment, 2017 (%)
Figure 34. Teva: Revenue Share By Region, 2017 (%)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to a new report titled, 'Cancer Pain Market by Type and Application: Global Opportunity Analysis and Industry Forecast, 2018 - 2025,' the global cancer pain market was valued at $5,285 million in 2017, and is expected to reach $7,545 million by 2025, growing at a CAGR of 4.5% from 2018 to 2025.

Cancer pain is chronic in nature and is commonly associated with cancer. It results from tissue damage, either due to the disease itself or due to different treatments such as chemotherapy, radiotherapy, or surgery. Cancer pain drugs are expected to exhibit significant market growth during the forecast period due to growth in demand for the drugs, surge in prevalence of cancer across the globe, increase in number of R&D activities to develop ideal cancer pain medications, and rise in the unmet needs for management of cancer pain.

Based on drug type, the global cancer pain market is categorized into opioids, non-opioids, and nerve blockers. The opioids segment was the major revenue contributor in 2017, and is anticipated to remain dominant during the forecast period due to increase in the adoption of opioids owing to rise in number of moderate to severe stage cancer patient population.

According to disease indication, the market is classified into lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer, and others. The lung cancer segment presently dominates the market and is expected to remain dominant during the forecast period due to increase in adoption of cancer pain medication for the treatment and rise in prevalence of lung cancer, globally.

Key Findings of the Cancer Pain Market:

Based on drug type, the opioids segment is expected to experience rapid growth in the market and is projected to grow at a CAGR of 5.0% from 2018 to 2025.
Based on disease indication, the lung cancer segment held more than one-fifth of the global market share in 2017 and is expected to remain dominant throughout the forecast period.
Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 5.4% during the forecast period.

North America accounted for more than one-third of the global market share in 2017 and is expected to remain dominant throughout the forecast period. This was attributed to the increase in demand for cancer pain therapeutics, high prevalence of cancer, wide availability of cancer pain drugs and trained medical professionals, and supportive reimbursement policies in the healthcare system. Asia-Pacific is expected to experience the highest growth rate during the forecast period majorly due to surge in incidence of cancer, with increase in adoption of cancer pain drugs for treatment of cancer.
Note: Product cover images may vary from those shown
5 of 4

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll